{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.","groups":[{"description":"Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.","id":"OG000","title":"Cabozantinib (XL184)"}],"paramType":"NUMBER","populationDescription":"9 participants are evaluable. 2 participants never started treatment.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Maximally Tolerated Dose","type":"PRIMARY","unitOfMeasure":"mg"}